Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells

Toxicology Letters

Volumn 231, Issue 1, 2014, Pages 55-61

  Jiang, Fei ^a,b   Wang, Xingxing ^b   Liu, Qinqiang ^c   Shen, Jian ^c   Li, Zhong ^b   Li, Yuan ^a,b   Zhang, Jianping ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Medical University   (China)

^c THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Arsenic trioxide; Hepatocellular carcinoma; MicroRNA 491; Signal transduction

Indexed keywords

ARSENIC TRIOXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MICRORNA; MICRORNA 491; SMAD3 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; 3' UNTRANSLATED REGION; ANGIOGENESIS INHIBITOR; MIRN491 MICRORNA, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE; SMAD3 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; DNA METHYLATION; ENZYME INACTIVATION; GENE EXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RNA INTERFERENCE; TIME; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

3' UNTRANSLATED REGIONS; ANGIOGENESIS INHIBITORS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; OXIDES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908334279     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.08.024     Document Type: Article

References (31)

1. Alhasan M.K., Liu L., Lewis M.A., Magnusson J., Mason R.P. Comparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors. PloS One 2012, 7:e46106.
2. Capece D., Fischietti M., Verzella D., Gaggiano A., Cicciarelli G., Tessitore A., Zazzeroni F., Alesse E. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. BioMed Res. Int. 2013, 2013:187204.
3. 3) on human breast cancer cells. J. Cell. Biochem. 2004, 93:173-187.
4. Cohen M.M. TGF beta/Smad signaling system and its pathologic correlates. Am. J. Med. Genet. A 2003, 116A:1-10.
5. Diepart C., Karroum O., Magat J., Feron O., Verrax J., Calderon P.B., Gregoire V., Leveque P., Stockis J., Dauguet N., Jordan B.F., Gallez B. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res. 2012, 72:482-490.
6. Ding S.J., Li Y., Shao X.X., Zhou H., Zeng R., Tang Z.Y., Xia Q.C. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 2004, 4:982-994.
7. Eaves C.J. Cancer stem cells: here, there, everywhere?. Nature 2008, 456:581-582.
8. Fei M., Lu M., Wang Y., Zhao Y., He S., Gao S., Ke Q., Liu Y., Li P., Cui X., Shen A., Cheng C. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med. Oncol. 2009, 26:178-185.
9. Ghavamzadeh A., Alimoghaddam K., Ghaffari S.H., Rostami S., Jahani M., Hosseini R., Mossavi A., Baybordi E., Khodabadeh A., Iravani M., Bahar B., Mortazavi Y., Totonchi M., Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann. Oncol. 2006, 17:131-134.
10. Gu F.M., Li Q.L., Gao Q., Jiang J.H., Zhu K., Huang X.Y., Pan J.F., Yan J., Hu J.H., Wang Z., Dai Z., Fan J., Zhou J. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol. Cancer 2011, 10:150.
11. He G., Dhar D., Nakagawa H., Font-Burgada J., Ogata H., Jiang Y., Shalapour S., Seki E., Yost S.E., Jepsen K., Frazer K.A., Harismendy O., Hatziapostolou M., Iliopoulos D., Suetsugu A., Hoffman R.M., Tateishi R., Koike K., Karin M. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 2013, 155:384-396.
12. Hogan K.A., Ravindran A., Podolsky M.A., Glick A.B. The TGFbeta1 pathway is required for NFkappaB dependent gene expression in mouse keratinocytes. Cytokine 2013, 64:652-659.
13. Kogan S.C. Medicine. Poisonous contacts. Science 2010, 328:184-185.
14. Li Y., Tang Z.Y., Ye S.L., Liu Y.K., Chen J., Xue Q., Chen J., Gao D.M., Bao W.H. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J. Gastroenterol. 2001, 7:630-636.
15. Li Y., Jiang R., Zhao Y., Xu Y., Ling M., Pang Y., Shen L., Zhou Y., Zhang J., Zhou J., Wang X., Liu Q. Opposed arsenite-mediated regulation of p53-survivin is involved in neoplastic transformation, DNA damage, or apoptosis in human keratinocytes. Toxicology 2012, 300:121-131.
16. Liu B., Pan S., Dong X., Qiao H., Jiang H., Krissansen G.W., Sun X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 2006, 97:675-681.
17. Liu Z., Bandyopadhyay A., Nichols R.W., Wang L., Hinck A.P., Wang S., Sun L.Z. Blockade of autocrine TGF-beta signaling inhibits stem cell phenotype survival, and metastasis of murine breast cancer cells. J. Stem Cell Res. Ther. 2012, 2:1-8.
18. Matise L.A., Palmer T.D., Ashby W.J., Nashabi A., Chytil A., Aakre M., Pickup M.W., Gorska A.E., Zijlstra A., Moses H.L. Lack of transforming growth factor-beta signaling promotes collective cancer cell invasion through tumor-stromal crosstalk. Breast Cancer Res. 2012, 14:R98.
19. Micalizzi D.S., Christensen K.L., Jedlicka P., Coletta R.D., Baron A.E., Harrell J.C., Horwitz K.B., Billheimer D., Heichman K.A., Welm A.L., Schiemann W.P., Ford H.L. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J. Clin. Invest. 2009, 119:2678-2690.
20. Mirzoeva S., Franzen C.A., Pelling J.C. Apigenin inhibits TGF-beta-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism. Mol. Carcinog. 2014, 53:598-609.
21. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
22. Sanchez-Elsner T., Botella L.M., Velasco B., Corbi A., Attisano L., Bernabeu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem. 2001, 276:38527-38535.
23. Shiota M., Zardan A., Takeuchi A., Kumano M., Beraldi E., Naito S., Zoubeidi A., Gleave M.E. Clusterin mediates TGF-beta-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res. 2012, 72:5261-5272.
24. Tsochatzis E.A., Meyer T., Burroughs A.K. Hepatocellular carcinoma. N. Engl. J. Med. 2012, 366(92):92-93. author reply.
25. Uchino K., Tateishi R., Shiina S., Kanda M., Masuzaki R., Kondo Y., Goto T., Omata M., Yoshida H., Koike K. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 2011, 117:4475-4483.
26. Wang X., Jiang F., Mu J., Ye X., Si L., Ning S., Li Z., Li Y. Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491. Toxicol. Lett. 2014, 227:75-83.
27. Wani A.A., Jafarnejad S.M., Zhou J., Li G. Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kappaB/interleukin-6 signaling pathway. Oncogene 2011, 30:2778-2788.
28. Wu K., Ding J., Chen C., Sun W., Ning B.F., Wen W., Huang L., Han T., Yang W., Wang C., Li Z., Wu M.C., Feng G.S., Xie W.F., Wang H.Y. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 2012, 56:2255-2267.
29. Zhao B., Ma Y., Xu Z., Wang J., Wang F., Wang D., Pan S., Wu Y., Pan H., Xu D., Liu L., Jiang H. Hydroxytyrosol, a natural molecule from olive oil, suppresses the growth of human hepatocellular carcinoma cells via inactivating AKT and nuclear factor-kappa B pathways. Cancer Lett. 2014, 347:79-87.
30. Zhong Z., Carroll K.D., Policarpio D., Osborn C., Gregory M., Bassi R., Jimenez X., Prewett M., Liebisch G., Persaud K., Burtrum D., Wang S., Surguladze D., Ng S., Griffith H., Balderes P., Doody J., Schwartz J.D., Youssoufian H., Rowinsky E.K., Ludwig D.L., Witte L., Zhu Z., Wu Y. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer stroma and immune cells. Clin. Cancer Res. 2010, 16:1191-1205.
31. Zhou Y., Li Y., Ye J., Jiang R., Yan H., Yang X., Liu Q., Zhang J. MicroRNA-491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition. Liver Int. 2013, 33:1271-1280.